Measles, mumps, rubella prevention: how can we do better?

References

• World Health Organization. Global measles and rubella strategic plan: 2012-2020. World Health Organization, Geneva, 2012. [cited 2020 Aug 19]. Available from https://apps.who.int/iris/bitstream/handle/10665/44855/9789241503396_eng.pdf?sequence=1
   Google Scholar
• Keja K, Chan C, Hayden G, et al. Expanded programme on immunization. World health Stat Q. 1988;41(2):59–63.
   PubMedGoogle Scholar
• Rasheed MAU, Hickman CJ, McGrew M, et al. Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood. Proc Natl Acad Sci U S A. 2019;116(38):19071–19076.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82(7):51–60.
   PubMedGoogle Scholar
• World Health Organization. Global vaccine action plan 2011–2020. WHO Library Cataloguing-in-Publication Data. 2013. [cited 2020 Mar 12]. Available from https://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/
   Google Scholar
• Orenstein WA, Cairns L, Hinman A, et al. Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: background and summary. Vaccine. 2018;36(Suppl 1):A35–A42.
   PubMed Web of Science ®Google Scholar
• Measles & Rubella Initiative. The measles and rubella strategic framework 2021-2030. [cited 2021 Jan 6]. Available from https://measlesrubellainitiative.org/measles-rubella-strategic-framework-2021-2030/.
   Google Scholar
• World Health Organization. Immunization agenda 2030: a global strategy to leave no one behind. [cited 2021 Jan 05]. Available from https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030
   Google Scholar
• Bankamp B, Hickman C, Icenogle JP, et al. Successes and challenges for preventing measles, mumps and rubella by vaccination. Curr Opin Virol. 2019;34:110–116.
   PubMed Web of Science ®Google Scholar
• Holzmann H, Hengel H, Tenbusch M, et al. Eradication of measles: remaining challenges. Med Microbiol Immunol. 2016;205(3):201–208.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2019 global summary. [cited 2020 Mar 13]. Available from http://apps.who.int/immunization_monitoring/globalsummary/schedules
   Google Scholar
• Demicheli V, Rivetti A, Debalini MG, et al. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012(2):CD004407
   Google Scholar
• Sood A, Mitra M, Joshi HA, et al. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: results of a randomized, comparative, active controlled phase III clinical trial. Hum Vaccin Immunother. 2017;13(7):1523–1530.
   PubMed Web of Science ®Google Scholar
• Hartfield M, Alizon S. Introducing the outbreak threshold in epidemiology. PLoS Pathog. 2013;9(6):e1003277.
   PubMed Web of Science ®Google Scholar
• Guerra FM, Bolotin S, Lim G, et al. The basic reproduction number (R 0) of measles: a systematic review. Lancet Infect Dis. 2017;17(12):e420–e428.
   PubMed Web of Science ®Google Scholar
• Delamater PL, Street EJ, Leslie TF, et al. Complexity of the basic reproduction number (R0). Emerg Infect Dis. 2019;25(1):1–4.
   PubMed Web of Science ®Google Scholar
• Funk S, Knapp JK, Lebo E, et al. Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination. BMC Med. 2019;17(1):180.
   PubMed Web of Science ®Google Scholar
• Roberts L. Is measles next? Science. 2015;348(6238):958–961, 963.
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Gay NJ, Kretzschmar M, et al. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect. 2000;125(3):635–650.
   PubMed Web of Science ®Google Scholar
• Lambert N, Strebel P, Orenstein W, et al. Rubella. Lancet. 2015;385(9984):2297–2307.
   PubMed Web of Science ®Google Scholar
• Measles vaccines: WHO position paper – April 2017. Wkly Epidemiol Rec. 2017;92(17):205–227.
   PubMedGoogle Scholar
• Gavi. Application guidelines: gavi’s support to countries. [cited 2020 Mar 13]. Available from https://www.gavi.org/sites/default/files/document/support/Application%20guidelines%20for%20all%20types%20of%20Gavi%20Support.pdf
   Google Scholar
• World Health Organization. Immunization coverage. [cited 2021 Jan 06]. Available from https://www.who.int/en/news-room/fact-sheets/detail/immunization-coverage
   Google Scholar
• Patel MK, Goodson JL, Alexander JP Jr, et al. Progress Toward Regional Measles Elimination — worldwide, 2000–2019. MMWR Morb Mortal Wkly Rep. 2020;69(45):1700–1705. DOI: 10.15585/mmwr.mm6945a6.
   PubMed Web of Science ®Google Scholar
• Dabbagh A, Laws RL, Steulet C, et al. Progress Toward Regional Measles Elimination — worldwide, 2000–2017. MMWR Morb Mortal Wkly Rep. 2018;67(47):1323–1329.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Plotkin S. The changing epidemiology of mumps in a high vaccination era. Lancet Infect Dis. 2019;19(2):118–119.
   PubMed Web of Science ®Google Scholar
• Beleni A-I, Borgmann S. Mumps in the vaccination age: global epidemiology and the situation in Germany. Int J Environ Res Public Health. 2018;15(8):1618.
   Web of Science ®Google Scholar
• Grant GB, Reef SE, Patel M, et al. Progress in Rubella and Congenital Rubella Syndrome Control and Elimination — worldwide, 2000 – 2016. MMWR Morb Mortal Wkly Rep. 2017;66(45):1256–1260 .
   PubMed Web of Science ®Google Scholar
• Zimmerman LA, Muscat M, Singh S, et al. Progress toward measles elimination — European region, 2009–2018. MMWR Morb Mortal Wkly Rep. 2019;68(17):396–401. DOI:10.15585/mmwr.mm6817a4.
   PubMed Web of Science ®Google Scholar
• Coombes R. Europe steps up action against vaccine hesitancy as measles outbreaks continue. BMJ. 2017;359:j4803.
   PubMed Web of Science ®Google Scholar
• Filia A, Bella A, Del Manso M, et al. Ongoing outbreak with well over 4,000 measles cases in Italy from January to end August 2017 − what is making elimination so difficult? Euro Surveill. 2017;22(37):30614.
   PubMedGoogle Scholar
• Cousins S. Measles: a global resurgence. Lancet Infect Dis. 2019;19(4):362–363.
   PubMed Web of Science ®Google Scholar
• Grammens T, Schirvel C, Leenen S, et al. Ongoing measles outbreak in Wallonia, Belgium, December 2016 to March 2017: characteristics and challenges. Euro Surveill. 2017;22(17):30524.
   PubMedGoogle Scholar
• Lewnard JA, Grad YH. Vaccine waning and mumps re-emergence in the United States. Sci Transl Med. 2018;10(433):eaao5945.
   PubMed Web of Science ®Google Scholar
• Westphal DW, Eastwood A, Levy A, et al. A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study. Lancet Infect Dis. 2019;19(2):177–184.
   PubMed Web of Science ®Google Scholar
• Marlow M, Even S, Hoban MT, et al. Universities’ experience with mumps outbreak response and use of a third dose of MMR vaccine. J Am Coll Health. 2021;69(1):53-58.
   PubMed Web of Science ®Google Scholar
• Veneti L, Borgen K, Borge KS, et al. Large outbreak of mumps virus genotype G among vaccinated students in Norway, 2015 to 2016. Euro Surveill. 2018;23(38):1700642.
   Google Scholar
• Aasheim ET, Inns T, Trindall A, et al. Outbreak of mumps in a school setting, United Kingdom, 2013. Hum Vaccin Immunother. 2014;10(8):2446–2449.
   PubMed Web of Science ®Google Scholar
• Barskey AE, Schulte C, Rosen JB, et al. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med. 2012;367(18):1704–1713.
   PubMed Web of Science ®Google Scholar
• Javelle E, Colson P, Parola P, et al. Measles, the need for a paradigm shift. Eur J Epidemiol. 2019;34(10):897–915.
   PubMed Web of Science ®Google Scholar
• Toffolutti V, McKee M, Melegaro A, et al. Austerity, measles and mandatory vaccination: cross-regional analysis of vaccination in Italy 2000–14. Eur J Public Health. 2019;29(1):123–127.
   PubMed Web of Science ®Google Scholar
• Chen RT, Moses JM, Markowitz LE, et al. Adverse events following measles—mumps—rubella and measles vaccinations in college students. Vaccine. 1991;9(5):297–299.
   PubMed Web of Science ®Google Scholar
• Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis. 1994;169(1):77–82.
   PubMed Web of Science ®Google Scholar
• Hersh BS, Fine PEM, Kent WK, et al. Mumps outbreak in a highly vaccinated population. J Pediatr. 1991;119(2):187–193.
   PubMed Web of Science ®Google Scholar
• Robertson SE, Cutts FT, Samuel R, et al. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 2: vaccination against rubella. Bull World Health Organ. 1997;75(1):69–80.
   PubMed Web of Science ®Google Scholar
• Lassi ZS, Naseem R, Salam RA, et al. The impact of the COVID-19 pandemic on immunization campaigns and programs: a systematic review. Int J Environ Res Public Health. 2021;18(3):988.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. COVID-19’s impact on measles vaccination coverage. Page last reviewed: November 11, 2020. [cited 2021 Mar 09]. Available from https://www.cdc.gov/globalhealth/measles/news/covid-impact-on-measles-vaccination.html
   Google Scholar
• Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006;5(3):101–117.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guide for clinical case management and infection prevention and control during a measles outbreak. License: CC BY-NC-SA 3.0 IGO. [cited 2021 Feb 03]. Available from https://apps.who.int/iris/handle/10665/331599
   Google Scholar
• Phadke VK, Bednarczyk RA, Salmon DA, et al. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA. 2016;315(11):1149–1158.
   PubMed Web of Science ®Google Scholar
• MacDonald NE. SAGE working group on vaccine hesitancy. vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161–4164.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Report of the SAGE Working Group on Vaccine Hesitancy. Oct 2014.[cited 2020 Mar 16]. Available from http://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf
   Google Scholar
• Larson HJ, Clarke RM, Jarrett C, et al. Measuring trust in vaccination: a systematic review. Hum Vaccin Immunother. 2018;14(7):1599–1609.
   PubMed Web of Science ®Google Scholar
• Larson HJ, Jarrett C, Eckersberger E, et al. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012. Vaccine. 2014;32(19):2150–2159.
   PubMed Web of Science ®Google Scholar
• Brown KF, Kroll JS, Hudson MJ, et al. Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review. Vaccine. 2010;28(26):4235–4248.
   PubMed Web of Science ®Google Scholar
• Jarrett C, Wilson R, O’Leary M, et al. Strategies for addressing vaccine hesitancy - A systematic review. Vaccine. 2015;33(34):4180–4190.
   PubMed Web of Science ®Google Scholar
• Sadaf A, Richards JL, Glanz J, et al. A systematic review of interventions for reducing parental vaccine refusal and vaccine hesitancy. Vaccine. 2013;31(40):4293–4304.
   PubMed Web of Science ®Google Scholar
• Montalti M, Kawalec A, Leoni E, et al. Measles immunization policies and vaccination coverage in EU/EEA countries over the last decade. Vaccines (Basel). 2020;8(1):86.
   Web of Science ®Google Scholar
• D’Ancona F, D’Amario C, Maraglino F, et al. The law on compulsory vaccination in Italy: an update 2 years after the introduction. Euro Surveill. 2019;24(26):1900371.
   Google Scholar
• Torjesen I. German parliament votes to make measles vaccination mandatory. BMJ. 2019;367:l6558.
   PubMed Web of Science ®Google Scholar
• Cantor JD. Mandatory measles vaccination in New York City - reflections on a bold experiment. N Engl J Med. 2019;381(2):101–103.
   PubMed Web of Science ®Google Scholar
• Yang YT, Studdert DM. Linking immunization status and eligibility for welfare and benefits payments: the Australian “No Jab, No Pay” legislation. JAMA. 2017;317(8):803–804.
   PubMed Web of Science ®Google Scholar
• Magurano F, Baggieri M, Mazzilli F, et al. Measles in Italy: viral strains and crossing borders. Int J Infect Dis. 2019;79:199–201.
   PubMed Web of Science ®Google Scholar
• Rovida F, Brianese N, Piralla A, et al. Outbreak of measles genotype H1 in Northern Italy originated from a case imported from Southeast Asia, 2017. Clin Microbiol Infect. 2019;25(4):526–528.
   PubMed Web of Science ®Google Scholar
• Heywood AE. Measles: a re-emerging problem in migrants and travellers. J Travel Med. 2018;25(1). https://doi.org/10.1093/jtm/tay118.
   Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Who is at risk for measles in the EU/EEA? Identifying susceptible groups to close immunity gaps towards measles elimination. Stockholm: ECDC; 2019. [cited 2020 Apr 16]. Available from https://www.ecdc.europa.eu/sites/default/files/documents/RRA-Measles-EU-EEA-May-2019.pdf
   Google Scholar
• Barnett ED, Walker PF. Role of immigrants and migrants in emerging infectious diseases. Med Clin North Am. 2008;92(6):1447–1458.
   PubMed Web of Science ®Google Scholar
• Mipatrini D, Stefanelli P, Severoni S, et al. Vaccinations in migrants and refugees: a challenge for European health systems. A systematic review of current scientific evidence. Pathog Glob Health. 2017;111(2):59–68.
   PubMed Web of Science ®Google Scholar
• Abbas M, Aloudat T, Bartolomei J, et al. Migrant and refugee populations: a public health and policy perspective on a continuing global crisis. Antimicrob Resist Infect Control. 2018;7:113.
   PubMed Web of Science ®Google Scholar
• Hargreaves S, Nellums LB, Ravensbergen SJ, et al. Divergent approaches in the vaccination of recently arrived migrants to Europe: a survey of national experts from 32 countries, 2017. Euro Surveill. 2018;23(41):1700772.
   Google Scholar
• George F, Valente J, Augusto GF, et al. Measles outbreak after 12 years without endemic transmission, Portugal, February to May 2017. Euro Surveill. 2017;22(23):30548.
   PubMedGoogle Scholar
• Currie J, Davies L, McCarthy J, et al. Measles outbreak linked to European B3 outbreaks, Wales, United Kingdom, 2017. Euro Surveill. 2017;22(42):17–00673.
   Google Scholar
• Hahné SJM, Nic Lochlainn LM, Van Burgel ND, et al. Measles outbreak among previously immunized healthcare workers, the Netherlands, 2014. J Infect Dis. 2016;214(12):1980–1986.
   PubMed Web of Science ®Google Scholar
• Fiebelkorn AP, Seward JF, Orenstein WA. A global perspective of vaccination of healthcare personnel against measles: systematic review. Vaccine. 2014;32(38):4823–4839.
   PubMed Web of Science ®Google Scholar
• Botelho-Nevers E, Cassir N, Minodier P, et al. Measles among healthcare workers: a potential for nosocomial outbreaks. Euro Surveill. 2011;16(2):19764.
   PubMedGoogle Scholar
• Haviari S, Benet T, Saadatian-Elahi M, et al. Vaccination of healthcare workers: a review. Hum Vaccin Immunother. 2015;11(11):2522–2537.
   PubMed Web of Science ®Google Scholar
• Melenotte C, Zandotti C, Gautret P, et al. Measles: is a new vaccine approach needed? Lancet Infect Dis. 2018;18(10):1060–1061.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Review of outbreaks and barriers to MMR vaccination coverage among hard-to-reach populations in Europe. Stockholm: ECDC; 2013. [cited 2020 Feb 26]. Available from https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/MMR-vaccination-hard-to-reach-population-review-2013.pdf
   Google Scholar
• Maltezou HC, Theodoridou K, Ledda C, et al. Vaccination of healthcare workers: is mandatory vaccination needed? Expert Rev Vaccines. 2019;18(1):5–13.
   PubMed Web of Science ®Google Scholar
• Bianchi FP, Mascipinto S, Stefanizzi P, et al. Prevalence and management of measles susceptibility in healthcare workers in Italy: a systematic review and meta-analysis. Expert Rev Vaccines. 2020;19(7):611–620.
   PubMed Web of Science ®Google Scholar
• Kopsidas J, Maroudi S, Tsopela GC, et al. Increasing healthcare workers’(HCW) uptake of seasonal influenza vaccination (SIV) in a tertiary pediatric hospital in Greece (ESP17-0994). 35th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2017), Madrid, Spain, May 23-27, 2017.
   Google Scholar
• Hiller U, Mankertz A, Köneke N, et al. Hospital outbreak of measles - Evaluation and costs of 10 occupational cases among healthcare worker in Germany, February to March 2017. Vaccine. 2019;37(14):1905–1909.
   PubMed Web of Science ®Google Scholar
• Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;86(29):301–316.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep. 1993;42(RR–4):1–18.
   Google Scholar
• Menson EN, Mellado MJ, Bamford A, et al. Guidance on vaccination of HIV-infected children in Europe. HIV Med. 2012;13(6):333–336.
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics PRIORIX. [cited 2020 Jul 16]. Available from https://gskpro.com/content/dam/global/hcpportal/en_MT/PDF/Homepage/Products/productlisting/priorix/PRIORIX-SPC-PL-PIL-JUN15.pdf
   Google Scholar
• Mutsaerts EAML, Nunes MC, Bhikha S, et al. Immunogenicity and safety of an early measles vaccination schedule at 6 and 12 months of age in human immunodeficiency virus (HIV)-unexposed and HIV-exposed, uninfected South African children. J Infect Dis. 2019;220(9):1529–1538.
   PubMed Web of Science ®Google Scholar
• Mutsaerts EAML, Nunes MC, Van Rijswijk MN, et al. Measles immunity at 4.5 years of age following vaccination at 9 and 15-18 months of age among human immunodeficiency virus (HIV)-infected, HIV-exposed-uninfected, and HIV-unexposed children. Clin Infect Dis. 2019;69(4):687–696.
   PubMed Web of Science ®Google Scholar
• Angel JB, Walpita P, Lerch RA, et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med. 1998;129(2):104–106.
   PubMed Web of Science ®Google Scholar
• Duncan CJA, Mohamad SMB, Young DF, et al. Human IFNAR2 deficiency: lessons for antiviral immunity. Sci Transl Med. 2015;7(307):307ra154.
   PubMed Web of Science ®Google Scholar
• Hambleton S, Goodbourn S, Young DF, et al. STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci U S A. 2013;110(8):3053–3058.
   PubMed Web of Science ®Google Scholar
• Grundy J, Biggs BA. The impact of conflict on immunisation coverage in 16 countries. Int J Health Policy Manag. 2019;8(4):211–221.
   PubMed Web of Science ®Google Scholar
• Page KR, Doocy S, Reyna Ganteaume F, et al. Venezuela’s public health crisis: a regional emergency. Lancet. 2019;393(10177):1254–1260.
   PubMed Web of Science ®Google Scholar
• Nandy R Immunization under fire. Unicef Connect. 2016 Apr 25. [cited 2020 Feb 24]. Available from https://blogs.unicef.org/blog/immunization-under-fire/
   Google Scholar
• Orenstein WA, Hinman A, Nkowane B, et al. Measles and rubella global strategic plan 2012–2020 midterm review. 2016. [cited 2020 Mar 16]. Available from http://www.who.int/immunization/sage/meetings/2016/october/1_MTR_Report_Final_Color_Sept_20_v2.pdf?ua=1
   Google Scholar
• Peyraud N, Quere M, Duc G, et al. A post-conflict vaccination campaign, Central African Republic. Bull World Health Organ. 2018;96(8):540–547.
   PubMed Web of Science ®Google Scholar
• Gavi. On the frontline: gavi’s support to fragile states. [cited 2020 Mar 16]. Available from https://www.gavi.org/news/media-room/frontline-gavis-support-fragile-states
   Google Scholar
• World Health Organization. Maintaining essential health services: operational guidance for the COVID-19 context interim guidance. [cited 2020 Jul 06]. Available from https://www.who.int/publications/i/item/covid-19-operational-guidance-for-maintaining-essential-health-services-during-an-outbreak
   Google Scholar
• Bramer CA, Kimmins LM, Swanson R, et al. Decline in child vaccination coverage during the COVID-19 pandemic - Michigan Care Improvement Registry, May 2016-May 2020. MMWR Morb Mortal Wkly Rep. 2020;69(20):630–631.
   PubMed Web of Science ®Google Scholar
• Saxena S, Skirrow H, Bedford H. Routine vaccination during covid-19 pandemic response. BMJ. 2020;369:m2392.
   PubMed Web of Science ®Google Scholar
• Marziano V, Poletti P, Trentini F, et al. Parental vaccination to reduce measles immunity gaps in Italy. Elife. 2019;8:e44942.
   PubMed Web of Science ®Google Scholar
• Portnoy A, Jit M, Helleringer S, et al. Impact of measles supplementary immunization activities on reaching children missed by routine programs. Vaccine. 2018;36(1):170–178.
   PubMed Web of Science ®Google Scholar
• Cutts FT, Dansereau E, Ferrari MJ, et al. Using models to shape measles control and elimination strategies in low- and middle-income countries: a review of recent applications. Vaccine. 2020;38(5):979–992.
   PubMed Web of Science ®Google Scholar
• Zewdie A, Letebo M, Mekonnen T. Reasons for defaulting from childhood immunization program: a qualitative study from Hadiya zone, Southern Ethiopia. BMC Public Health. 2016;16(1):1240.
   PubMed Web of Science ®Google Scholar
• Immunization Unit of the Pan American Health Organization. Measles elimination: field guide. Washington, D.C.: PAHO, 2005. (Scientific and Technical Publication No. 605). [cited 2020 Feb 26]. Available from http://new.paho.org/hq/dmdocuments/2010/FieldGuide_Measles_2ndEd_e.pdf
   Google Scholar
• Orenstein WA, Strebel PM, Papania M, et al. Measles eradication: is it in our future? Am J Public Health. 2000;90(10):1521–1525.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Mumps outbreaks: a problem in need of solutions. J Infect. 2018;76(6):503–506.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Mumps: a Pain in the Neck. J Pediatric Infect Dis Soc. 2018;7(2):91–92.
   PubMed Web of Science ®Google Scholar
• Cardemil CV, Dahl RM, James L, et al. Effectiveness of a third dose of MMR vaccine for mumps outbreak control. N Engl J Med. 2017;377(10):947–956.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention (CDC). CDC guidance for public health authorities on use of a 3rd dose of MMR vaccine during mumps outbreaks. [cited 2019 Nov 21]. Available from https://www.cdc.gov/mumps/health-departments/MMR3.html
   Google Scholar
• Kaaijk P, Wijmenga-Monsuur AJ, Van Houten MA, et al. A third dose of measles-mumps-rubella vaccine to improve immunity against mumps in young adults. J Infect Dis. 2020;221(6):902–909.
   PubMed Web of Science ®Google Scholar
• Fiebelkorn AP, Coleman LA, Belongia EA, et al. Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. Open Forum Infect Dis. 2014;1(3):ofu094.
   PubMedGoogle Scholar
• Vaccines Europe. From vaccines shortages to sustainable vaccine supply: vaccines Europe Position. [cited 2019 Nov 20]. Available from http://www.vaccineseurope.eu/wp-content/uploads/2016/06/VE-Paper_shortagesFIN-2.pdf
   Google Scholar
• Brinkman ID, De Wit J, Smits GP, et al. Early measles vaccination during an outbreak in the Netherlands: short-term and long-term decreases in antibody responses among children vaccinated before 12 months of age. J Infect Dis. 2019;220(4):594–602.
   PubMed Web of Science ®Google Scholar
• Vashishtha VM, Yewale VN, Bansal CP, et al. IAP perspectives on measles and rubella elimination strategies. Indian Pediatr. 2014;51(9):719–722.
   PubMed Web of Science ®Google Scholar
• Javed N, Saqib MAN, Hassan Bullo MM, et al. Seroprevalence of transplacentally acquired measles antibodies in unvaccinated infants at nine months of age and its relation to the feeding practices. BMC Infect Dis. 2019;19(1):587.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Early vaccination: a provisional measure to prevent measles in infants. Lancet Infect Dis. 2019;19(11):1157–1158.
   PubMed Web of Science ®Google Scholar
• van der Maas, Woudenberg T, Hahne SJ, et al. Tolerability of early measles-mumps-rubella vaccination in infants aged 6–14 months during a measles outbreak in the Netherlands in 2013–2014. J Infect Dis. 2016;213(9):1466–1471.
   PubMed Web of Science ®Google Scholar
• Hardt K, Bonanni P, King S, et al. Vaccine strategies: optimising outcomes. Vaccine. 2016;34(52):6691–6699.
   PubMed Web of Science ®Google Scholar
• Hansen JS, Thysen SM, Rodrigues A, et al. Is early measles vaccination associated with stronger survival benefits than later measles vaccination? BMC Public Health. 2018;18(1):984.
   PubMed Web of Science ®Google Scholar
• Do VA, Biering-Sorensen S, Fisker AB, et al. Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: a Randomized, Controlled Trial in Guinea-Bissau. J Infect Dis. 2017;215(8):1188–1196.
   PubMed Web of Science ®Google Scholar
• Smits G, Stabell Benn C, Whittle H, et al. Maternal measles antibodies and their influence on all-cause mortality following measles vaccination: an alternative to measure very low maternal antibody levels. Clin Infect Dis. 2019;68(10):1758–1760.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N, Cornaglia G. Barriers to the vaccination of children and adolescents and possible solutions. Clin Microbiol Infect. 2014;20:25–31.
   PubMed Web of Science ®Google Scholar
• Expert Panel on effective ways of investing in Health (EXPH). Preliminary report on vaccination programmes and health systems in Europe, 2018 Sept 26. [cited 2020 Aug 17]. Available from https://ec.europa.eu/health/sites/health/files/expert_panel/docs/020_vaccinationpgms_en.pdf
   Google Scholar
• The King’s Fund. Understanding pressures in general practice. 2016. [cited 2020 Feb 27]. Available from https://www.kingsfund.org.uk/sites/default/files/field/field_publication_file/Understanding-GP-pressures-Kings-Fund-May-2016.pdf
   Google Scholar
• Wighton K Access to children’s GP appointments linked to use of emergency departments. Imperial College London News. Published on 2016 Jan 20. [cited 2020 Feb 27]. Available from https://www.imperial.ac.uk/news/170333/access-childrens-gp-appointments-linked-emergency/
   Google Scholar
• The National Institute for Health and Care Excellences (NICE). Quality standard topic: vaccine uptake in under 19s. Date of Quality Standards Advisory Committee meeting. 2016 Jun 29th. [cited 2020 Feb 27]. Available from https://www.nice.org.uk/guidance/qs145/documents/briefing-paper
   Google Scholar
• Pereira JA, Quach S, Heidebrecht CL, et al. Barriers to the use of reminder/recall interventions for immunizations: a systematic review. BMC Med Inform Decis Mak. 2012;12:145.
   PubMed Web of Science ®Google Scholar
• Chachou MJ, Mukinda FK, Motaze V, et al. Electronic and postal reminders for improving immunisation coverage in children: protocol for a systematic review and meta-analysis. BMJ Open. 2015;5(10):e008310.
   PubMed Web of Science ®Google Scholar
• Betsch C, Böhm R, Chapman GB. Using behavioral insights to increase vaccination policy effectiveness. Policy Insights Behav Brain Sci. 2015;2(1):61–73.
   Google Scholar
• Harvey H, Reissland N, Mason J. Parental reminder, recall and educational interventions to improve early childhood immunisation uptake: a systematic review and meta-analysis. Vaccine. 2015;33(25):2862–2880.
   PubMed Web of Science ®Google Scholar
• Jacobson Vann JC, Szilagyi P. Patient reminder and patient recall systems to improve immunization rates. Cochrane Database Syst Rev. 2005;3:Cd003941.
   Google Scholar
• Williams N, Woodward H, Majeed A, et al. Primary care strategies to improve childhood immunisation uptake in developed countries: systematic review. JRSM Short Reports. 2011;2(10):81. DOI:10.1258/shorts.2011.011112.
   PubMedGoogle Scholar
• NHS England. Optimising your invite-reminder systems for childhood immunisations. 2017. [cited 2019 Feb 12]. Available from https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2018/06/Good-Practice-Immunisation-Invite-Reminder-Guide.pdf
   Google Scholar
• Lonergan K, Latif A, Beaney T, et al. Implementing the evidence: are call/recall systems for immunisations feasible in general practice? Vaccine Immunol Open Access J. 2018;1:11–15.
   Google Scholar
• Crocker-Buque T, Edelstein M, Mounier-Jack S. Interventions to reduce inequalities in vaccine uptake in children and adolescents aged 19 years: a= systematic=/19years. J Epidemiol Community Health. 2017;71(1):87–97.
   PubMed Web of Science ®Google Scholar
• Oyo-Ita A, Wiysonge CS, Oringanje C, et al. Interventions for improving coverage of childhood immunisation in low- and middle-income countries. Cochrane Database Syst Rev. 2016;7(7):CD008145.
   PubMed Web of Science ®Google Scholar
• Driessen J, Olson ZD, Jamison DT, et al. Comparing the health and social protection effects of measles vaccination strategies in Ethiopia: an extended cost-effectiveness analysis. Soc Sci Med. 2015;139:115–122.
   PubMed Web of Science ®Google Scholar
• Vandelaer J, Olaniran M. Using a school-based approach to deliver immunization—Global update. Vaccine. 2015;33(5):719–725.
   PubMed Web of Science ®Google Scholar
• Perman S, Turner S, Ramsay AIG, et al. School-based vaccination programmes: a systematic review of the evidence on organisation and delivery in high income countries. BMC Public Health. 2017;17(1):252.
   PubMed Web of Science ®Google Scholar
• Patel MK, Gibson R, Cohen A, et al. Global landscape of measles and rubella surveillance. Vaccine. 2018;36(48):7385–7392.
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Gagnier MC, Colson KE, et al. Missed opportunities for measles, mumps, and rubella (MMR) immunization in Mesoamerica: potential impact on coverage and days at risk. PLoS One. 2015;10(10):e0139680.
   PubMed Web of Science ®Google Scholar
• Carryn S, Feyssaguet M, Povey M, et al. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: a 10-year follow-up. Vaccine. 2019;37(36):5323–5331.
   PubMed Web of Science ®Google Scholar
• Gillet Y, Steri GC, Behre U, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months–2 years or 2–6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009;27(3):446–453.
   PubMed Web of Science ®Google Scholar
• Johnson CE, Kumar ML, Whitwell JK, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J. 1996;15(8):687–692.
   PubMed Web of Science ®Google Scholar
• Nic Lochlainn LM, De Gier B, Van Der Maas N, et al. Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(11):1235–1245.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO immunological basis for immunization series. Module 7: Measles. Update 2020. [cited 2021 Feb 12]. Available from https://apps.who.int/iris/bitstream/handle/10665/331533/9789241516655-eng.pdf?ua=1
   Google Scholar
• Paunio M, Hedman K, Davidkin I, et al. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect. 2000;124(2):263–271.
   PubMed Web of Science ®Google Scholar
• Haralambieva IH, Kennedy RB, Ovsyannikova IG, et al. Current perspectives in assessing humoral immunity after measles vaccination. Expert Rev Vaccines. 2019;18(1):75–87.
   PubMed Web of Science ®Google Scholar
• Bitzegeio J, Majowicz S, Matysiak-Klose D, et al. Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity. Euro Surveill. 2019;24(17):1800529.
   Google Scholar
• Bangor‐Jones RD, Dowse GK, Giele CM, et al. A prolonged mumps outbreak among highly vaccinated Aboriginal people in the Kimberley region of Western Australia. Med J Aust. 2009;191(7):398–401.
   PubMed Web of Science ®Google Scholar
• Vygen S, Fischer A, Meurice L, et al. Waning immunity against mumps in vaccinated young adults, France 2013. Euro Surveill. 2016;21(10):30156.
   PubMedGoogle Scholar
• Livingston KA, Rosen JB, Zucker JR, et al. Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City. Vaccine. 2014;32(3):369–374.
   PubMed Web of Science ®Google Scholar
• Davidkin I, Jokinen S, Broman M, et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197(7):950–956.
   PubMed Web of Science ®Google Scholar
• Rubin SA, Link MA, Sauder CJ, et al. Recent mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol. 2012;86(1):615–620.
   PubMed Web of Science ®Google Scholar
• Hamami D, Cameron R, Pollock KG, et al. Waning immunity is associated with periodic large outbreaks of mumps: a mathematical modeling study of Scottish data. Front Physiol. 2017;8:233.
   PubMed Web of Science ®Google Scholar
• Crooke SN, Haralambieva IH, Grill DE, et al. Seroprevalence and durability of rubella virus antibodies in a highly immunized population. Vaccine. 2019;37(29):3876–3882.
   PubMed Web of Science ®Google Scholar
• Davidkin I, Peltola H, Leinikki P, et al. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination A 15-year follow-up in Finland. Vaccine. 2000;18(27):3106–3112.
   PubMed Web of Science ®Google Scholar
• Kung W-J, Shih C-T, Shih Y-L, et al. Faster waning of the rubella-specific immune response in young pregnant women immunized with MMR at 15 months. Am J Reprod Immunol. 2020;84(4):e13294.
   PubMed Web of Science ®Google Scholar
• Hanna‐Wakim R, Yasukawa LL, Sung P, et al. Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis. 2008;197(12):1669–1675.
   PubMed Web of Science ®Google Scholar
• Hyöty H, Räsänen L, Lehto M, et al. Cell-mediated and humoral immunity to mumps virus antigen. Acta Pathol Microbiol Immunol Scand C. 1986;94(5):201–206.
   Google Scholar
• Terada K, Hagihara K, Oishi T, et al. Cellular and humoral immunity after vaccination or natural mumps infection. Pediatr Int. 2017;59(8):885–890.
   PubMed Web of Science ®Google Scholar
• Vandermeulen C, Clement F, Roelants M, et al. Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination. J Infect Dis. 2009;199(10):1457–1460.
   PubMed Web of Science ®Google Scholar
• Lambert ND, Haralambieva IH, Ovsyannikova IG, et al. Characterization of humoral and cellular immunity to rubella vaccine in four distinct cohorts. Immunol Res. 2014;58(1):1–8.
   PubMed Web of Science ®Google Scholar
• O’Shea S, Best JM, Banatvala JE. Viremia, Virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis. 1983;148(4):639–647.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention (CDC). Measles. Genetic analysis of measles virus. Lab Tools. Page last reviewed: 2020 Nov 5. [cited 2021 Mar 09]. Available from https://www.cdc.gov/measles/lab-tools/genetic-analysis.html
   Google Scholar
• Bellini WJ. Genetic diversity of wild-type measles viruses: implications for global measles elimination programs. Emerg Infect Dis. 1998;4(1):29–35.
   PubMed Web of Science ®Google Scholar
• Rota PA, Brown K, Mankertz A, et al. Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis. 2011;204suppl 1:S514–523.
   PubMed Web of Science ®Google Scholar
• Gastañaduy PA, Funk S, Lopman BA, et al. Factors associated with measles transmission in the United States during the postelimination era. JAMA Pediatr. 2020;174(1):56–62.
   PubMed Web of Science ®Google Scholar
• Pacenti M, Maione N, Lavezzo E, et al. Measles virus infection and immunity in a suboptimal vaccination coverage setting. Vaccines (Basel). 2019;7(4):199.
   Web of Science ®Google Scholar
• Cui A, Zhu Z, Hu Y, et al. Mumps epidemiology and mumps virus genotypes circulating in Mainland China during 2013-2015. PLoS One. 2017;12(1):e0169561.
   PubMed Web of Science ®Google Scholar
• Gouma S, Sane J, Gijselaar D, et al. Two major mumps genotype G variants dominated recent mumps outbreaks in the Netherlands (2009–2012). J Gen Virol. 2014;95(5):1074–1082.
   PubMed Web of Science ®Google Scholar
• Hindiyeh MY, Aboudy Y, Wohoush M, et al. Characterization of large mumps outbreak among vaccinated Palestinian refugees. J Clin Microbiol. 2009;47(3):560–565.
   PubMed Web of Science ®Google Scholar
• Malayan J, Warrier A, Ramanan PV, et al. Unnoticeable mumps infection in India: does MMR vaccine protect against circulating mumps virus genotype C? Int J Biotechnol Bioeng. 2012;6:1011–1017.
   Google Scholar
• Park SH. Resurgence of mumps in Korea. Infection & Chemotherapy. 2015;47(1):1–11.
   PubMed Web of Science ®Google Scholar
• Peltola H, Kulkarni PS, Kapre SV, et al. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin Infect Dis. 2007;45(4):459–466.
   PubMed Web of Science ®Google Scholar
• Vermeire T, Barbezange C, Francart A, et al. Sera from different age cohorts in Belgium show limited cross-neutralization between the mumps vaccine and outbreak strains. Clin Microbiol Infect. 2019;25(7):907.e901–907.e906.
   PubMed Web of Science ®Google Scholar
• Willocks LJ, Guerendiain D, Austin HI, et al. An outbreak of mumps with genetic strain variation in a highly vaccinated student population in Scotland. Epidemiol Infect. 2017;145(15):3219–3225.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis. 2008;47(11):1458–1467.
   PubMed Web of Science ®Google Scholar
• L’Huillier AG, Eshaghi A, Racey CS, et al. Laboratory testing and phylogenetic analysis during a mumps outbreak in Ontario, Canada. Virol J. 2018;15(1):98.
   PubMed Web of Science ®Google Scholar
• Wei Y, Wilkinson K, Rusk R, et al. Large community mumps outbreak in Manitoba, Canada, September 2016–December 2018. Canada Commun Dis Rep. 2020;46(4):70–76.
   PubMedGoogle Scholar
• Gouma S, Ten Hulscher HI, Schurink-van ‘T Klooster TM, et al. Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infection. Vaccine. 2016;34(35):4166–4171. DOI:10.1016/j.vaccine.2016.06.063.
   PubMed Web of Science ®Google Scholar
• May M, Rieder CA, Rowe RJ. Emergent lineages of mumps virus suggest the need for a polyvalent vaccine. Int J Infect Dis. 2018;66:1–4.
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001;19(17–19):2688–2691.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571.
   PubMed Web of Science ®Google Scholar
• Gilbert SC, Warimwe GM. Rapid development of vaccines against emerging pathogens: the replication-deficient simian adenovirus platform technology. Vaccine. 2017;35(35):4461–4464.
   PubMed Web of Science ®Google Scholar
• Poudel A, Lau ETL, Deldot M, et al. Pharmacist role in vaccination: evidence and challenges. Vaccine. 2019;37(40):5939–5945.
   PubMed Web of Science ®Google Scholar
• Bishai D, Johns B, Nair D, et al. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda. J Infect Dis. 2011;204Suppl 1(Suppl 1):S107–S115.
   PubMed Web of Science ®Google Scholar
• Dabral M. Cost-effectiveness of supplementary immunization for measles in India. Indian Pediatr. 2009;46(11):957–962.
   PubMed Web of Science ®Google Scholar
• Kaucley L, Levy P. Cost-effectiveness analysis of routine immunization and supplementary immunization activity for measles in a health district of Benin. Cost Eff Resour Alloc. 2015;13:14.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Mitigating the impact of COVID-19 on control of vaccine-preventable diseases: a health risk management approach focused on catch-up vaccination. Copenhagen: WHO Regional Office for Europe; 2020. Licence: CC BY-NC-SA 3.0 IGO. [cited 2021 Mar 03]. Available from https://apps.who.int/iris/bitstream/handle/10665/334248/WHO-EURO-2020-1086-40832-55187-eng.pdf?sequence=1&isAllowed=y
   Google Scholar
• Senessie C, Gage GN, Von Elm E. Delays in childhood immunization in a conflict area: a study from Sierra Leone during civil war. Conflict and Health. 2007;1:14.
   PubMedGoogle Scholar
• Eriksen J, Davidkin I, Kafatos G, et al. Seroepidemiology of mumps in Europe (1996–2008): why do outbreaks occur in highly vaccinated populations? Epidemiol Infect. 2013;141(3):651–666.
   PubMed Web of Science ®Google Scholar
• Andersson U, Bird G, Britton S. A sequential study of human B lymphocyte function from birth to two years of age. Acta Paediatr Scand. 1981;70(6):837–842.
   PubMed Web of Science ®Google Scholar
• Herrera OR, Thornton TA, Helms RA, et al. MMR vaccine: when is the right time for the second dose? J Pediatr Pharmacol Ther. 2015;20(2):144–148.
   PubMedGoogle Scholar
• Braeckman T, Theeten H, Roelants M, et al. Can Flanders resist the measles outbreak? Assessing vaccination coverage in different age groups among Flemish residents. Epidemiol Infect. 2018;146(8):1043–1047.
   PubMed Web of Science ®Google Scholar
• Draeger E, Bedford HE, Elliman DAC. Should measles vaccination be compulsory? BMJ. 2019;365:l2359.
   PubMed Web of Science ®Google Scholar
• Dubé E, Laberge C, Guay M, et al. Vaccine hesitancy: an overview. Hum Vaccines Immunother. 2013;9(8):1763–1773.
   PubMed Web of Science ®Google Scholar
• Schnaith AM, Evans EM, Vogt C, et al. An innovative medical school curriculum to address human papillomavirus vaccine hesitancy. Vaccine. 2018;36(26):3830–3835.
   PubMed Web of Science ®Google Scholar